Lumen Therapeutics had been a development stage biopharmaceutical company focused on proprietary drugs based on oligo-L-arginine. At the time of Lume's SBIR Phase I in 2010, the company's lead product has completed a Phase I/IIa clinical trial for the prevention of vein graft failure after bypass graft surgery. Lumenâs lead product (LT-1951) exploited the unique ability of small peptides containing Lâarginine to penetrate into blood vessels and prevent vascular stenosis by increasing the local concentration of nitric oxide. Such peptides have been shown to block the occurrence of vascular stenosis in animals that have undergone vein graft procedures similar to those used in CABG, PABG and AVS. Lumen's founders - the Stanford University scientists who did early preclinical research in this field -- discovered and patented Lumen's lead product candidates. Thes expectation was that the proprietary peptide agents would prove to be highly effective in the prevention of vascular stenosis in CABG, PABG, and AVS. The evidence would seem to sugges that the firm is nolonger operation
